- Home
- MNY vs ALGS Comparison
MNY vs ALGS Comparison
Compare MNY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNY | ALGS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Singapore | United States |
| Employees | 240 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 34.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MNY | ALGS |
|---|---|---|
| Price | $0.92 | $5.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $39.33 |
| AVG Volume (30 Days) | 11.2K | ★ 105.2K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | $19.58 | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.78 | $3.98 |
| 52 Week High | $2.40 | $13.69 |
Technical Indicators
Market Signals| Indicator | MNY | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 56.92 |
| Support Level | $0.78 | $4.80 |
| Resistance Level | $1.03 | $5.94 |
| Average True Range (ATR) | 0.05 | 0.50 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 84.07 |
Price Performance
Historical ComparisonAbout MNY MoneyHero Limited
MoneyHero Ltd is a tech- and AI-powered personal finance aggregation and comparison platform and a digital insurance brokerage provider in Greater Southeast Asia. It operates in Singapore, Hong Kong, Taiwan and the Philippines. Its brand portfolio includes B2C platforms MoneyHero, SingSaver, Money101, Moneymax and Seedly, as well as the B2B platform Creatory. The company has four operating and reportable segments: Hong Kong, Singapore, the Philippines, and Taiwan. The Hong Kong segment generates the majority of the revenue.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.